Gilotrif

Chemical Nameafatinib
Dosage FormTablet (oral; 20mg, 30mg, and 40mg)
Drug ClassKinase inhibitors
SystemRespiratory
CompanyBoehringer Ingelheim Pharmaceuticals
Approval Year2013

Indication

  • For the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have non-resistant epidermal growth factor receptor (EGFR) mutations as detected by an FDA-approved test.
  • For the treatment of patients with metastatic, squamous NSCLC progressing after platinum-based chemotherapy.
Last updated on 4/27/2021

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Gilotrif (afatinib) Prescribing Information2019Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT